The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey
Open accessAbstract
Background: Fabry disease is a rare X-linked lysosomal storage disorder characterised by severe multisystemic involvement that leads to major organ failure and premature death in affected men and women. Over the past 7 years, the Fabry Outcome Survey (FOS) has collected data on the natural history of Fabry disease, and the long-term efficacy and safety of enzyme-replacement therapy. This paper provides an update on the first analysis of FOS data. Design: Baseline data on clinical manifestations and causes of death in a cohort of 1453 patients (699 male, 754 female) from 19 countries worldwide were analysed. Causes of death of affected relatives were analysed separately. Results: The most frequently reported signs and symptoms of Fabry disease were neurological. Cardiac, ocular, gastrointestinal, dermatological, auditory and renal manifestations were also common. The principal causes of death among 181 affected relatives of patients in FOS (most of whom had died before 2001) were renal failure in males (42%) and cerebrovascular disease in females (25%). In contrast, of the 42 patients enrolled in FOS whose deaths were reported between 2001 and 2007, cardiac disease was the main cause of death in both male (34%) and female (57%) patients. Conclusion: These data suggest that the importance of renal disease as a cause of death in patients with Fabry disease is decreasing while the importance of cardiac disease is increasing. This pattern probably reflects improvements in the management of renal disease in patients with Fabry disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
van Gelder, H. A. E. (1961) · The Two Reformations in the 16th Century · doi:10.1007/978-94-011-9562-1_10 · Cited by 1,652
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
European cardiovascular disease statistics
Allender, S. E., Scarborough, P., Peto, V., Rayner, M., Leal, J., Luengo-Fernández, R., & Gray, A. M. (2008) · Deakin Research Online (Deakin University) · Cited by 1,459
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., & Desnick, R. J. (2006) · The American Journal of Human Genetics · doi:10.1086/504601 · Cited by 1,008
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Ries, M., & Beck, M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01309.x · Cited by 848
Self-citationMacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
α-Galactosidase A deficiency. Fabry disease
Desnick, R. J. (2001) · Cited by 605
Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy
Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W. J., & Elliott, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000012626.81324.38 · Cited by 570
Self-citationFemales with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
BRANTON, M. H., SCHIFFMANN, R., SABNIS, S. G., MURRAY, G. J., QUIRK, J. M., ALTARESCU, G., GOLDFARB, L., BRADY, R. O., BALOW, J. E., AUSTIN, H. A., et al. (2002) · Medicine · doi:10.1097/00005792-200203000-00003 · Cited by 461
Fabry Disease: Perspectives from 5 Years of FOS
Mehta, A. B., Beck, M., & Sunder–Plassmann, G. (2006) · Cited by 443
Self-citationGermain, D. P., Waldek, S., Banikazemi, M., Bushinsky, D. A., Charrow, J., Desnick, R. J., Lee, P., Loew, T., Vedder, A. C., Abichandani, R., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080816 · Cited by 438
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., Bultas, J., Lee, P., Sims, K., Brodie, S. E., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000237866.70357.c6 · Cited by 411
Linhart, A., Kampmann, C., Zamorano, J. L., Sunder-Plassmann, G., Beck, M., Mehta, A., Elliott, P. M., & on behalf of European FOS Investigators (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm153 · Cited by 397
Self-citationWeidemann, F., Breunig, F., Beer, M., Sandstede, J., Turschner, O., Voelker, W., Ertl, G., Knoll, A., Wanner, C., & Strotmann, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000091253.71282.04 · Cited by 389
Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., & Desnick, R. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp031 · Cited by 368
Hughes, D. A., Elliott, P. M., Shah, J., Zuckerman, J., Coghlan, G., Brookes, J., & Mehta, A. B. (2008) · Heart · doi:10.1136/hrt.2006.104026 · Cited by 318
Self-citationNatural history of Fabry disease in females in the Fabry Outcome Survey
Deegan, P. B., Baehner, A. F., Barba Romero, M.-Á., Hughes, D. A., Kampmann, C., & Beck, M. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036327 · Cited by 304
Self-citationNarrative Review: Fabry Disease
Clarke, J. T. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00007 · Cited by 202
Self-citationAgalsidase Alfa and Kidney Dysfunction in Fabry Disease
West, M., Nicholls, K., Mehta, A., Clarke, J. T. R., Steiner, R., Beck, M., Barshop, B. A., Rhead, W., Mensah, R., Ries, M., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080870 · Cited by 162
Self-citationWhybra, C., Miebach, E., Mengel, E., Gal, A., Baron, K., Beck, M., & Kampmann, C. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181a23bec · Cited by 94
Self-citationRecommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
Ortíz, A., Oliveira, J. P., Wanner, C., Brenner, B. M., Waldek, S., & Warnock, D. G. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0806 · Cited by 80
Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease
Feriozzi, S., Schwarting, A., Sunder–Plassmann, G., West, M. L., & Cybulla, M. (2008) · American Journal of Nephrology · doi:10.1159/000168482 · Cited by 69
Self-citationWitsch‐Baumgartner, M., Clayton, P. T., Clusellas, N., Haas, D., Kelley, R. I., Krajewska‐Walasek, M., Lechner, S., Rossi, M., Zschocke, J., & Utermann, G. (2005) · Human Mutation · doi:10.1002/humu.9328 · Cited by 30
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Germain, D. P., Charrow, J., Desnick, R. J., Guffon, N., Kempf, J., Lachmann, R. H., Lemay, R., Linthorst, G. E., Packman, S., Scott, C. R., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102797 · Cited by 368
Waldek, S., Patel, M. R., Banikazemi, M., Lemay, R., & Lee, P. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bb05bb · Cited by 353
Mehta, A., Beck, M., Elliott, P., Giugliani, R., Linhart, A., Sunder-Plassmann, G., Schiffmann, R., Barbey, F., Ries, M., & Clarke, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61493-8 · Cited by 273
Self-citationOttinger, E., Kao, M., Carrillo-Carrasco, N., Yanjanin, N., Shankar, R., Janssen, M., Brewster, M., Scott, I., Xu, X., Cradock, J., et al. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131127160118 · Cited by 121
Metadata
- Authors
- Mehta, A., Clarke, J. T. R., Giugliani, R., Elliott, P., Linhart, A., Beck, M., & Sunder-Plassmann, G.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2009-05-26
- Volume
- 46
- Issue
- 8
- Pages
- 548-552
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2165008949
- Cited by
- 309
- References
- 27
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.